ABSTRACT
La vitamina D tiene acciones antiinflamatorias y aumenta la expresión de péptidos antimicrobianos. Niveles bajos de 25 hidroxivitamina D (25OHD) se relacionan con la obesidad. El inhibidor secretor de proteasa leucocitaria (SLPI) es un péptido serina proteasa no glicosilado con actividad antimicrobiana y antiinflamatoria que podría asociarse con la obesidad y la inflamación. Objetivo: evaluar la correlación entre la 25OHD y el SLPI en las mujeres y su relación con la obesidad. Para ello, se incluyeron 32 mujeres posmenopáusicas (69±6 años), sin patologías o medicaciones que pudieran afectar el estado inflamatorio. Se midieron el peso corporal (PC) (kg) y esta-tura (m) y se calculó el índice de masa corporal (IMC). Se determinaron los niveles de SLPI (ng/mL) (ELISA) y 25OHD (ng/mL) (RIA). La masa grasa (densitometría) (gr) se normalizó por el PC para obtener el porcentaje de masa (PMG). Resultados (X±SD): el IMC fue de 30,3±6,9 y el PMG de 43,9±9,6. SLIP osciló entre 1,9 y 29,7 (13,1±6,8) y la 25OHD entre 8,2 y 48 ng/mL (22,1±13,7). El PMG, pero no el IMC, se correlacionó negativamente con el SLIP (r=-0,64, p=0,01) y la 25HOD (r=-0,69, p=0,01). El SLPI se correlacionó con la 25OHD (r=0,61, p=0,01). Tomando las mujeres obesas con suficiencia de 25OHD, la correlación entre ambos fue altamente significativa (r=0,97; p<0,0001). Conclusiones: además de favorecer la liberación de péptidos antimicrobianos, nuestros resultados mostraron que niveles adecuados de 25OHD correlacionan positivamente con SLPI en obesidad. Serían necesarios estudios adicionales en una población más amplia para aclarar si esta correlación es clínicamente relevante. (AU)
Vitamin D has anti-inflammatory actions, increasing the expression of antimicrobial peptides. Low levels of 25hydroxyvitamin D (25OHD) are associated with obesity. Secretory leukocyte protease inhibitor (SLPI) is a non-glycosylated serine protease peptide with antimicrobial and anti-inflammatory activity, which could be associated with obesity and inflammation. Objective: to evaluate the correlation between 25OHD and SLPI in women and its relationship with obesity. Thirty-two postmenopausal women (69±6 years), without conditions or medications that could affect their inflammatory status, were included. Body weight (BW) (kg) and height (m) were measured and body mass index (BMI) was calculated. SLPI (ng/mL) (ELISA) and 25OHD (ng/mL) (RIA) levels were determined. Fat mass (densitometry) (gr) was normalized by BW to obtain percent fat mass (PFM). Results (X±SD): BMI was 30.3±6.9 and PFM was 43.9±9.6. SLIP ranged from 1.9 to 29.7 (13.1±6.8) and 25OHD ranged from 8.2 to 48 ng/mL (22.1±13.7). PFM, but not BMI, negatively correlated with SLIP (r=-0.64, p=0.01) and 25HOD (r=-0.69, p=0.01). SLPI correlated with 25OHD (r=0.61, p=0.01). For obese women with 25OHD sufficiency, the correlation between both was highly significant (r=0.97; p<0.0001). Conclusions: In addition to favoring the release of antimicrobial peptides, our results showed that adequate 25OHD levels correlate positively with SLIP in obesity. Further studies in a larger population would be necessary to clarify whether this correlation is clinically relevant. (AU)
Subject(s)
Humans , Female , Middle Aged , Aged , Aged, 80 and over , Vitamin D/analogs & derivatives , Vitamin D/metabolism , Postmenopause/metabolism , Secretory Leukocyte Peptidase Inhibitor/metabolism , Obesity/metabolism , Vitamin D/blood , Biomarkers , Body Mass Index , Adipose Tissue/metabolism , Secretory Leukocyte Peptidase Inhibitor/blood , X-Ray Absorption Spectroscopy , Preliminary DataABSTRACT
Purpose: To assess the frequency of dysmobility syndrome (DS) in a group of postmenopausal women, to determine the frequency of fragility fractures in these patients, and to compare the frequency of fragility fractures and other clinical, biochemical, densitometric, and muscle health characteristics between patients with and without DS. Methods: Postmenopausal women aged ≥ 60 years were invited to participate in a muscle health study program in our bone clinic. The diagnosis of DS was considered when at least three of the following factors were present: osteoporosis, ≥1 fall in the preceding year, low muscle mass, slow gait speed, low grip strength, and high-fat mass. The cohort was divided into patients with DS and without DS. Results: The mean age in the study cohort (n = 250) was 70.36± 7.72 years. DS was diagnosed in 77 patients (30.8 %). A history of falls in the preceding year and the prevalence of fragility fractures were more frequent in patients with DS in comparison with the control group (60% vs. 19%, p <0.001 and 42% vs 17%, p <0.001, respectively). Furthermore, the history of fragility fractures was significantly associated with the presence of DS (OR 4.92, 95% CI 2.3-10.4, p <0.001). Discussion: A significant association was found between DS and a history of fragility fractures. Although this new concept needs further investigation, it seems that the identification of various compartments affected by the aging process results in an opportunity to better predict major adverse events in the elderly. (AU)
Propósito: Evaluar la frecuencia del síndrome de dismovilidad (SD) en un grupo de mujeres posmenopáusicas, determinar la frecuencia de fracturas por fragilidad en estas pacientes y comparar la frecuencia de fracturas por fra-gilidad y otras características clínicas, bioquímicas, densitométricas y de salud muscular entre pacientes con y sin SD. Métodos: Se invitó a mujeres posmenopáusicas de edad ≥60 años a participar en un pro-grama de estudio de la salud muscular en nuestra clínica ósea. Se consideró el diagnóstico de SD cuando estaban presentes al menos tres de los siguientes factores: osteoporosis, ≥1 caída en el año anterior, baja masa muscular, velocidad de marcha lenta, baja fuerza de prensión y masa grasa elevada. La cohorte se dividió en pacientes con SD y sin SD. Resultados: La edad media de la cohorte de estudio (n = 250) fue de 70,36± 7,72 años. Se diagnosticó SD en 77 pacientes (30,8%). Los antecedentes de caídas en el año anterior y la prevalencia de fracturas por fragilidad fue-ron más frecuentes en los pacientes con SD en comparación con el grupo de control (60% frente a 19%, p <0,001 y 42% frente a 17%, p <0,001, respectivamente). Además, el ante-cedente de fracturas por fragilidad se asoció significativamente con la presencia de SD (OR 4,92; IC 95% 2,3-10,4; p <0,001). Discusión: Se encontró una asociación significativa entre el SD y los antecedentes de frac-turas por fragilidad. Aunque este nuevo concepto requiere más investigación, parece que la identificación de diversos compartimentos afectados por el proceso de envejecimiento brinda la oportunidad de predecir mejor los principales acontecimientos adversos en los ancianos. (AU)
Subject(s)
Humans , Female , Middle Aged , Aged , Postmenopause , Fractures, Bone/epidemiology , Frailty/epidemiology , Osteoporosis/complications , Bone Density , Adipose Tissue , Prevalence , Cross-Sectional Studies , Frail Elderly , Risk Assessment/methods , Fractures, Bone/prevention & control , Mobility Limitation , Muscle Strength , Walking SpeedABSTRACT
Los fibromas ováricos son tumores benignos poco frecuentes, generalmente unilaterales, que se presentan principalmente en mujeres perimenopáusicas y posmenopáusicas. Los síntomas pueden variar y en algunos casos están asociados a ascitis y derrame pleural, conocido como síndrome de Meigs. Se presenta un caso de una paciente de 55 años de edad con antecedentes de hipertensión arterial y asma bronquial, quién acude a ginecólogo por dolor en fosa ilíaca derecha de tres meses de evolución. Se realizan diferentes estudios incluyendo ecografía y tomografía abdomino-pélvica, los cuales revelan una tumoración sólida bilateral de ovarios. Se realiza histerectomía abdominal total más salpingo-oforectomía bilateral y a pesar de sus características, el estudio histopatológico hace el diagnóstico de fibroma bilateral. La presentación clínica de los fibromas de ovario es inespecífica, por lo que suelen confundirse con patología maligna del ovario u otras patologías benignas de útero u ovario, constituyendo un reto para el diagnóstico preoperatorio(AU)
Ovarian fibromas are rare tumors that mainly occur in perimenopausal and postmenopausal women. Symptoms can vary, and in some cases, they may be associated with ascites and pleural effusion, known as Meigs Syndrome. The article presents the case of a 55-year-old patient with a history of hypertension and bronchial asthma, who visit a gynecologist due to pain in the right iliac fossa of three months duration. Various studies were performed, including ultrasound and abdominal and pelvic CT, which reveal the presence of solid bilateral ovarian tumors. The patient undergoes a total hysterectomy and bilateral salpingo-oophorectomy and despite it's characteristics, the histopathological study makes the diagnosis of bilateral ovarian fibroma with no signs of malignancy. The clinical presentation of ovarian fibromas is nonspecific, often leading to confusion with malignant ovarian pathology or other benign uterine or ovarian conditions, representing a challenge for preoperative diagnosis(AU)
Subject(s)
Humans , Female , Middle Aged , Ovarian Cysts , Postmenopause , Fibroma , Ovarian Neoplasms , UltrasonographyABSTRACT
BACKGROUND: Menopause is often associated with musculoskeletal complications like demineralization of bone, loss of muscle mass, and degenerative joint diseases. Osteoarthritis of the knee is the most common degenerative joint disorder among post-menopausal women. There is a complex interaction between perceived anxiety, experience of pain, and limitations of function among post-menopausal women. AIM: To determine the association of anxiety levels in postmenopausal women with osteoarthritis in worsening balance and walking speed. METHODS: This cross-sectional study design was conducted between May and July 2023, according to STROBE guidelines. Post-menopausal females with knee osteoarthritis were recruited from a private hospital, in Chennai, India. Based on the pain anxiety symptom scale (PASS-20) score they were categorized into women with and without anxiety. All participants underwent the Timed Up and Go test (TUG), and 4-meter walk test to identify their balance and walking speed. The collected data were analyzed appropriately using Chisquare statistics and regression methods. RESULTS: The mean age of 100 participants recruited in this study was 49.66 ± 6.3 years. The average time of onset of osteoarthritis in the participants was 49.28 months. The study identified that 49% of post-menopausal women with osteoarthritis had anxiety symptoms. Anxiety was significantly associated with an increase in age (P = 0.017) and duration from attaining menopause (P = 0.005). TUG test performance was significantly poor (P = 0.005) in individuals with anxiety. Unadjusted and adjusted linear regression demonstrated that anxiety is not associated with balance and walking speed in postmenopausal women with knee osteoarthritis. CONCLUSION: The presence of anxiety in postmenopausal women with osteoarthritis did not affect balance and walking speed outcomes. Age, duration of menopause, and body weight were found to be significantly associated.
INTRODUÇÃO: A menopausa está frequentemente associada a complicações músculo-esqueléticas, como desmineralização óssea, perda de massa muscular e doenças articulares degenerativas. A osteoartrite do joelho é a doença articular degenerativa mais comum entre mulheres na pós-menopausa. Existe uma interação complexa entre ansiedade percebida, experiência de dor e limitações funcionais entre mulheres na pós-menopausa. OBJETIVO: Determinar a associação dos níveis de ansiedade em mulheres pós-menopáusicas com osteoartrite no agravamento do equilíbrio e da velocidade de marcha. MÉTODOS: Este desenho de estudo transversal foi realizado entre maio e julho de 2023, de acordo com as guidelines STROBE. Mulheres na pós-menopausa com osteoartrose do joelho foram recrutadas num hospital privado, em Chennai, Índia. Com base na pontuação da escala de sintomas de ansiedade e dor (PASS-20), foram categorizadas em mulheres com e sem ansiedade. Todas as participantes foram submetidos ao teste Timed Up and Go (TUG) e ao teste de marcha de 4 metros para identificar o equilíbrio e a velocidade de marcha. Os dados recolhidos foram analisados adequadamente através de estatística qui-quadrado e métodos de regressão. RESULTADOS: A idade média das 100 participantes recrutados neste estudo foi de 49,66 ± 6,3 anos. O tempo médio de início da osteoartrite nas participantes foi de 49,28 meses. O estudo identificou que 49% das mulheres na pós-menopausa com osteoartrite apresentavam sintomas de ansiedade. A ansiedade esteve significativamente associada ao aumento da idade (P = 0,017) e à duração da menopausa (P = 0,005). O desempenho no teste TUG foi significativamente fraco (P = 0,005) nos indivíduos com ansiedade. A regressão linear não ajustada e ajustada demonstrou que a ansiedade não está associada ao equilíbrio e à velocidade de marcha em mulheres pósmenopáusicas com osteoartrose do joelho. CONCLUSÃO: A presença de ansiedade em mulheres na pós-menopausa com osteoartrite não afetou os resultados de equilíbrio e velocidade de marcha. A idade, a duração da menopausa e o peso corporal estiveram significativamente associados.
Subject(s)
Anxiety , Postmenopause , Osteoarthritis, KneeABSTRACT
INTRODUCTION: Age-related decline in pulmonary function and functional capacity is seen in adults. The menopausal process leads to a decline in pulmonary function and functional capacity which is essential in maintaining independence in daily life. OBJECTIVE: The present study aimed to explore the association of pulmonary function with functional capacity among middle-aged women. METHODS: One hundred and eight female participants aged 4055 years were included in this cross-sectional study; depending on their menstrual history participants were classified as premenopausal and postmenopausal. After initial screening and assessment, six-minute walk test (6MWT) and pulmonary function (FEV1, FVC, FEV1/FVC) were recorded as per standardised guidelines. The mean and standard deviation for all continuous variables were calculated. Correlations were estimated using Pearson's coefficient of correlation. A comparison of premenopausal and postmenopausal groups was done by independent t-test. A two-tailed p-value < 0.05 was considered statistically significant. RESULTS: There were significant differences in values of six-minute walk distance (6MWD) and pulmonary function values of pre and postmenopausal women (p < 0.05). The Pearson coefficient of correlation showed significant association of FEV1, FVC and FEV1/FVC with 6MWD among middle-aged women. There was fair positive correlation of FEV1 (r = 0.391, p = 0.002) and FEV1/ FVC (r = 0.395, p = 0.002) with 6MWD among postmenopausal women. CONCLUSION: There exists a fair positive correlation of pulmonary function with 6MWD among middle-aged women particularly postmenopausal women. Early screening of respiratory health and functional capacity should be initiated for middle-aged women as a preventive strategy.
INTRODUÇÃO: O declínio da função pulmonar e da capacidade funcional relacionado à idade é observado em adultos. O processo menopausal leva ao declínio da capacidade pulmonar e funcional, essencial para a manutenção da independência na vida diária. OBJETIVO: O presente estudo teve como objetivo explorar a associação da função pulmonar com a capacidade funcional em mulheres de meia idade. MÉTODOS: Cento e oito participantes do sexo feminino com idade entre 40 e 55 anos foram incluídas neste estudo transversal; dependendo da história menstrual, as participantes foram classificadas como pré-menopausa e pós-menopausa. Após triagem e avaliação inicial, teste de caminhada de seis minutos (TC6M) e função pulmonar (VEF1, CVF, VEF1/CVF) foram registrados de acordo com diretrizes padronizadas. Foram calculados média e desvio padrão para todas as variáveis contínuas. As correlações foram estimadas pelo coeficiente de correlação de Pearson. A comparação do grupo pré-menopausa e pós-menopausa foi feita por teste t independente. Um valor de p bicaudal < 0,05 foi considerado estatisticamente significativo. RESULTADOS: Houve diferenças significativas nos valores da distância caminhada de seis minutos (DC6M) e nos valores da função pulmonar de mulheres pré e pós-menopausa (p < 0,05). O coeficiente de correlação de Pearson mostrou associação significativa de VEF1, CVF e VEF1/CVF com a DC6M entre mulheres de meia idade. Houve correlação positive moderada do VEF1 (r = 0,391, p = 0,002) e VEF1/CVF (r = 0,395, p = 0,002) com a DC6M entre mulheres na pós-menopausa. CONCLUSÃO: Existe correlação positiva moderada da função pulmonar com a DC6M entre mulheres de meia idade, particularmente mulheres na pós-menopausa. O rastreio precoce da saúde respiratória e da capacidade funcional deve ser iniciado nas mulheres de meia idade como estratégia preventiva.
Subject(s)
Respiratory Function Tests , Women's Health , PostmenopauseABSTRACT
Abstract Objective: This meta-analysis of randomized controlled trials (RCTs) aimed to update evidence on the effectiveness and safety of laser therapy for treating genitourinary syndrome of menopause (GSM). Data sources: Manuscripts published until May 2023 were systematically searched in PubMed; Embase; Scopus; Web of Science; CENTRAL; CINAHL; and clinical trial databases (www.trialscentral.org, www.controlled-trials.com, and clinicaltrials.gov), with no language and year of publication restriction. Studies selection: RCTs with women diagnosed with GSM, and the intervention was vaginal laser therapy (CO2-laser or Er: YAG-laser) comparing with placebo (sham therapy), no treatment or vaginal estrogen therapy. Data collection: Two authors evaluated the publications for inclusion based on the title and abstract, followed by reviewing the relevant full-text articles. Disagreements during the review process were addressed by consensus, with the involvement of a third author. Data synthesis: Twelve RCTs, representing a total of 5147 participants, were included in this review. Vaginal health index (VHI) significantly improved in the carbon dioxide laser (CO2-laser) therapy group (MD=2.21; 95% CI=1.25 to 3.16), while dyspareunia (MD=−0.85; 95% CI=−1.59 to −0.10), dryness (MD=−0.62; 95% CI=−1.12 to −0.12) and burning (MD= −0.64; 95% CI=−1.28 to −0.01) decreased. No serious adverse effects were reported. Conclusion: CO2-laser increases VHI score and decreases dyspareunia, dryness and burning, especially when compared to sham-laser. However, the certainty of the evidence is low, thus preventing the recommendation of laser therapy for GSM management.
Subject(s)
Humans , Female , Middle Aged , Aged , Menopause , Postmenopause , Female Urogenital Diseases , Laser TherapyABSTRACT
Abstract Objective: To analyze the amount of muscle and the presence of sarcopenia in postmenopausal women using different methods, verifying the agreement between them as to skeletal muscle mass (SMM). Methods: This cross-sectional observational study was conducted with postmenopausal women aged ≥ 50 years. SMM was obtained from a predictive equation, Bioelectrical Impedance (BIA), and Dual Energy X-Ray Absorptiometry (DXA). The skeletal muscle mass index (SMI) and the appendicular skeletal muscle mass index (ASMI) were calculated. The cut-off point of SMI was determined for the population itself. The agreement between the SMI obtained using the different methods was verified. Sarcopenia was diagnosed according to the criteria proposed by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). The significance level adopted for all tests was 5.0%. Results: A total of 112 women were evaluated, with an average age of 66.1 ± 5.65 years. Among them, 51.8% were sufficiently active and 43.8% were overweight and obese. The SMI cut-offs were 6.46 kg/m2 for the predictive equation and 7.66 kg/m2 for BIA, with high sensitivity and specificity. There was an excellent agreement in the identification of SMM by the predictive equation (0.89 [0.824-0.917], p < 0.001) and BIA (0.92 [0.883-0.945], p < 0.001), in reference to DXA. The prevalence of sarcopenia was 0.9%, 1.8%, and 2.7% according to BIA, DXA, and the predictive equation, respectively. Conclusion: The predictive equation showed the expected agreement in estimating skeletal muscle mass in postmenopausal women, offering a viable and accurate alternative.
Subject(s)
Humans , Female , Middle Aged , Aged , Body Composition , Anthropometry , Electric Impedance , Postmenopause , Muscle, Skeletal , Overweight , Sarcopenia , ObesityABSTRACT
Introducción: La osteoporosis es una enfermedad esquelética difusa caracterizada por una disminución generalizada de la resistencia ósea, que predispone a un mayor riesgo de fracturas por fragilidad y está reconocida como un grave problema de salud. Objetivo: Determinar la masa ósea en mujeres de edad mediana y algunos factores relacionados con ella. Métodos: Se realizó un estudio descriptivo transversal en mujeres de edad mediana del Policlínico 19 de abril. De la planilla de recolección de datos se extrajeron: edad, color de la piel, etapa climatérica, número de partos, meses de lactancia, resultados hormonales. Se realizó densitometría para determinar mujeres con hueso normal, baja masa ósea u osteopenia y osteoporosis, y se asociaron con algunos factores de riesgo. Resultados: Se estudiaron 82 mujeres. El 67,07 por ciento tuvo masa ósea normal en la columna lumbar, un 19,51 por ciento baja masa ósea u osteopenia y un 13,42 por ciento osteoporosis. En la cadera izquierda la mayoría (91,46 por ciento) presentó masa ósea normal. De las perimenopáusicas, una entre 50 y 54 años presentó baja masa ósea; en posmenopáusicas predominó la osteoporosis en el grupo de 50-54 (50 por ciento), en las de 55-59, las que tenían hueso normal y osteopenia (41,2 por ciento cada una). En las posmenopáusicas, las que tenían la piel blanca fueron las que presentaron mayor afectación de la masa ósea. A mayor tiempo de posmenopausia menor masa ósea (p= 0,031*), a niveles más elevados de hormona luteinizante (p= 0,000) y foliculoestimulante (p= 0,000), menor densidad mineral ósea en la columna lumbar y cadera izquierda; a niveles más elevados de estradiol (p= 0,000), mayor densidad mineral ósea en ambas localizaciones. Conclusiones: Se concluye que la mayoría de las mujeres de edad mediana del policlínico 19 de abril tenían hueso normal; la osteoporosis predominó en los grupos de mayor edad y el color de la piel blanca. Mayor tiempo de posmenopausia y niveles elevados de hormona luteinizante y foliculoestimulante se asociaron con mala masa ósea; niveles elevados de estradiol con mejor masa ósea(AU)
Introduction: Osteoporosis is a diffuse skeletal disease characterized by a generalized decrease in bone resistance, which predisposes patients to an increased risk of fragility fractures and is recognized as a serious health problem. Objective: To determine bone mass in middle-aged women and some factors related to it. Methods: A descriptive and cross-sectional study was carried out in middle-aged women from the Policlínico 19 de Abril. The following data were extracted from the data collection form: age, skin color, climacteric stage, number of deliveries, breastfeeding months, hormonal results. Densitometry was performed to determine women with normal bone, low bone mass or osteopenia and osteoporosis, and these were associated with some risk factors. Results: A group of 82 women were studied. Of them, 67.07percent had normal bone mass in the lumbar spine, 19.51percent had low bone mass or osteopenia, and 13.42percent ad osteoporosis. On the left hip, the majority (91.46percent) had normal bone mass. Of the perimenopausal women, one aged 50-54 years had low bone mass; among postmenopausal women, osteoporosis predominated in the 50-54 age group (50percent), as well as in those aged 55-59, those with normal bone mass and osteopenia (41.2percent for each condition). In the postmenopausal women, those with white skin were the most affected in bone mass. The longer the postmenopausal period, the lower the bone mass (p = 0.031*); the higher the levels of luteinizing hormone (p = 0.000) and the follicle stimulating hormone (p = 0.000), the lower bone mineral density on the lumbar spine and left hip; the higher the levels of estradiol (p = 0.000), the higher bone mineral density on both locations. Conclusions: Most middle-aged women from the Policlínico April 19 were concluded to have normal bone; osteoporosis predominated in older age groups and white skin color. Longer postmenopausal time and higher levels of luteinizing hormone and the follicle stimulating hormone were associated with poor bone mass; high levels of estradiol were associated with better bone mass(AU)
Subject(s)
Humans , Female , Women , Osteoporosis, Postmenopausal/epidemiology , Postmenopause/physiology , Middle Aged , Epidemiology, Descriptive , Cross-Sectional StudiesABSTRACT
Introducción: El factor de riesgo más importante para el desarrollo del síndrome metabólico (SM) es la obesidad, un estado pro inflamatorio con alteraciones sistémicas y locales vinculadas al crecimiento tumoral, siendo un determinante en el desarrollo del cáncer de mama en la posmenopausia, en su pronóstico y en la eficacia del tratamiento. El objetivo del presente estudio fue determinar la asociación entre el SM y el Cáncer de Mama en mujeres posmenopáusicas comparradas con un grupo control. Materiales y métodos: El estudio fue de diseño observacional, analítico; se llevó a cabo en el Hospital de SOLCA-Guayaquil entre enero a diciembre del 2019. El muestreo fue no probabilístico. Se incluyeron casos de mujeres de 50 70 años con patología de mama. Las variables fueron presencia de síndrome metabólico y diagnóstico de cáncer de mama en mujeres posmenopaúsicas. Se utilizó Chi cuadrado, Odds Ratio, el intervalo de confianza al 95 % y valor P < 0.05 para revisar la significancia estadística. Resultados: Ingresaron al estudio 157 casos, 107 en el grupo con cáncer de mama (G1) y 50 mujeres (31 %) sin patología maligna (G2). La edad en G1 fue de 59.9±9.9 años en G2 55.5±5.5 (P=0.001). El índice de masa corporal fue 29.05±1.2 en G1 y 26.80±1.3 en G2 (P<0.001). OR del SM para el desarrollo de Cáncer de mama fue 4.60 (IC 95% 2.23-9.51 ) P<0.0001. OR del SM para el desarrollo de cáncer de mama en mujeres menores a 54 años fue de 0.22 (0.069-0.72), P=0.0118. No hubo asociaciones por tipo histológico. Conclusión: Existe asociación entre el SM y el cáncer de mama en mujeres posmenopáusicas, por lo que se debe considerar la salud metabólica como un factor de riesgo clínicamente relevante y modificable para el desarrollo del cáncer.
Introduction: The most critical risk factor for developing metabolic syndrome (MS) is obesity, a pro-inflammatory state with systemic and local alterations linked to tumor growth. It is a determinant in developing postmenopausal breast cancer in its prognosis. and the efficacy of treatment. This study aimed to determine the association between MS and Breast Cancer in postmenopausal women compared to a control group. Materials and methods: The study had an observational, analytical design at the SOLCA-Guayaquil Hospital between January and December 2019. The sampling was non-probabilistic. Cases of women between 50 and 70 years of age with breast pathology were included. The variables were the presence of metabolic syndrome and diagnosis of breast cancer in postmenopausal women. Chi-square, Odds Ratio, 95% confidence interval, and P value < 0.05 were used to review statistical significance. Results: 157 cases entered the study, 107 in the group with breast cancer (G1) and 50 women (31%) without malignancy (G2). The age in G1 was 59.9±9.9 years in G2 55.5±5.5 (P=0.001). The body mass index was 29.05±1.2 in G1 and 26.80±1.3 in G2 (P<0.001). OR of the MS for the development of breast cancer was 4.60 (95% CI 2.23-9.51) P<0.0001. OR of the MS for the development of breast cancer in women under 54 years of age was 0.22 (0.069-0.72), P=0.0118. There were no associations by histological type. Conclusion: There is an association between MS and breast cancer in postmenopausal women, so metabolic health should be considered a clinically relevant and modifiable risk factor for cancer development.
Subject(s)
Humans , Adult , Breast Neoplasms , Metabolic Syndrome , PostmenopauseABSTRACT
Objetivo: Determinar la relación de triglicéridos basales, con el riesgo a desarrollar enfermedades cardiovasculares en mujeres posmenopáusicas. Método: Estudio descriptivo, observacional y transversal, donde a 31 pacientes posmenopáusicas y sin antecedentes de enfermedades cardiometabólicas, se les determinó parámetros antropométricos (peso, talla, índice de masa corporal -IMC-); perfil lipídico en ayunas (colesterol total, triglicéridos o TG, lipoproteínas de baja y alta densidad -LDL, HDL-), por método enzimático colorimétrico, apolipoproteína B 100 (Apo B-100) por inmunodifusión radial, índices matemáticos LDL/Apo B-100y TG/HDL y cálculo de colesterol no-HDL. Resultados: los promedio y desviación de las variables fueron: edad:59±5 años con tiempo de posmenopausia: 8,77±3,92 años; IMC:27,6±4,4 kg/m.; colesterol total: 194±36 mg/dl; triglicéridos: 85±35 mg/dl; HDL: 33±8 mg/dl; LDL: 144±33 mg/dl; no-HDL: 159±37 mg/dl; Apo B-100: 172±246 mg/dl; LDL/Apo B-100: 1,15±0,03 y TG/HDL: 4,46±1,28. Discusión: Las pacientes se encontraron con sobrepeso, triglicéridos normales, colesterol total y LDL aumentado y las HDL bajas. El LDL-C/Apo B-100-100, que se relaciona con el tamaño y densidad de LDL, estuvo por debajo de 1,3 indicando la presencia de partículas pequeñas-densas, mientras TG/HDL, que se usa para estimar riesgo cardiovascular, estuvo por encima del corte establecido de 3,5. Conclusiones: Al relacionar los triglicéridos basales con LDL/Apo B-100 y TG/HDL, se observa que a partir del valor de triglicéridos de 100 mg/dl, se observa la presencia de partículas de lipoproteínas pequeñas-densas, y un alto riesgo cardiovascular, por lo que es necesario en mujeres posmenopáusicas el seguimiento a partir del valor de triglicéridos en 100 mg/dL ya que pudiera implicar el desarrollo de enfermedades cardiovasculares, en esta población(AU)
Objective: To determine the relationship of basal triglycerides with the risk of developing cardiovascular disease in postmenopausal women. Method: Descriptive, observational and cross-sectional study, where 31 postmenopause patients with no history of cardiometabolic disease were determined anthropometric parameters (weight, height, BMI); fasting lipid profile (total cholesterol, triglycerides or TG, LDL,HDL, by colorimetric enzymatic method), Apo B-100 (byradial immunodiffusion), LDL/Apo B-100 and TG/HDL mathematical indices and calculation of non-HDL cholesterol. Results: the mean and deviation of the variables were: age:59±5 years with postmenopause time: 8.77±3.92 years; BMI:27.6±4.4 kg/m2; total cholesterol: 194±36 mg/dl; triglycerides:85±35 mg/dl; HDL: 33±8 mg/dl; LDL: 144±33 mg/dl; non-HDL: 159±37 mg/dl; Apo B-100: 172±246 mg/dl; LDL/Apo B-100: 1.15±0.03 and TG/HDL: 4.46±1.28. Discussion: Patients were found to be overweight, normal triglycerides, total and LDL cholesterol high, and low HDL. LDL-C/ApoB-100-100, which is related to LDL size and density, was below 1.3 indicating the presence of small-dense particles, while TG/HDL, which is used to estimate cardiovascular risk, was above the established cut-off of 3.5. Conclusions: When relating the basal triglycerides with LDL/Apo B-100 and TG/HDL, it is observed that from the triglyceride value of 100mg/dl, the presence of small-dense lipoprotein particuals anda high cardiovascular risk is observed, so it is necessary in postmenopausal women to follow up from the triglycerid evalue in 100 mg/dL since it could imply the development of cardiovascular diseases, in this population(AU)
Subject(s)
Humans , Female , Middle Aged , Triglycerides , Cardiovascular Diseases , PostmenopauseABSTRACT
Introduction: The high prevalence of low vitamin B12 serum levels has been recognized as a public health problem in Latin America; however, the current magnitude of this deficiency in Colombia is uncertain. Low levels of vitamin B12 can induce clinical and subclinical hematological and neurological disorders. Epidemiological studies have demonstrated a relationship between vitamin B12 deficiency and cardiovascular diseases (CVDs). However, the role of vitamin B12 in insulin resistance has been poorly studied. Objective: This study aimed to evaluate the relationship between vitamin B12 serum levels and biochemical and anthropometric markers related to CVDs and insulin resistance in postmenopausal women from Colombia Caribbean. Methods: Correlational, descriptive study. By convenience sampling, 182 postmenopausal women from the medical consultation service of a health institution were linked. Serum vitamin B12 levels, anthropometric variables (body mass index, abdominal perimeter), and biochemical variables (glycemia, insulin, lipid profile, HOMA IR) were evaluated. Results: The average value of the vitamin B12 serum level was 312.5 ± 122.5 pg/mL (230.6 ± 90.4 pmol/L); 46.7% of the women had less than adequate levels of 300 pg/mL (> 221 pmol/L), and 9. 9% were deficient, with levels of less than 200 pg/mL (148 pmol/L). The women with metabolic syndrome were 63.7%, and according to HOMA IR, 52.7 % had insulin resistance. A significant inverse relationship was shown between serum vitamin B12 levels with basal glycemic (P =0.002) and HOMA-IR (P =0.040). Conclusions: A significant inverse relationship between vitamin B12 levels and basal glycemia and HOMA-IR was observed. These findings highlight vitamin B12 deficiency in postmenopausal women and suggest nutritional supplementation.Keywords: Vitamin B12, Insulin resistance, Diet, Postmenopause, Cardiovascular diseases (AU).
Introdução: A alta prevalência de baixos níveis séricos de vitamina B12 foi reconhecida como um problema de saúde pública na América Latina, mas a magnitude atual dessa deficiência na Colômbia é incerta. Baixos níveis de vitamina B12 podem induzir distúrbios hematológicos e neurológicos clínicos e subclínicos. Na verdade, estudos epidemiológicos demonstram uma relação entre deficiência de vitamina B12 e doenças cardiovasculares (DCVs). No entanto, o papel da vitamina B12 na resistência à insulina tem sido pouco estudado. Objetivo: O objetivo deste estudo foi avaliar a relação entre os níveis séricos de vitamina B12 e marcadores bioquímicos e antropométricos relacionados com doenças cardiovasculares e resistência à insulina em mulheres pós-menopáusicas da Colômbia Caribe. Métodos: Estudo correlacional, descritivo. Por amostragem de conveniência, foram vinculadas 182 mulheres na pós-menopausa do serviço de consulta médica de uma instituição de saúde. Níveis séricos de vitamina B12, variáveis antropométricas (índice de massa corporal, perímetro abdominal) e variáveis bioquímicas (glicemia, insulina, perfil lipídico, HOMA IR) foram avaliadas. Resultados: O valor médio do nível sérico de vitamina B12 foi de 312,5 ± 122,5 pg/mL (230,6 ± 90,4 pmol/L); 46,7% das mulheres tinham níveis abaixo do adequado de 300 pg/mL (> 221 pmol/L), e 9,9% eram deficientes, com níveis abaixo de 200 pg/mL (148 pmol/L).As mulheres com síndrome metabólica foram 63,7% e, segundo o HOMA IR, 52,7% apresentavam resistência à insulina. Uma relação inversa significativa entre os níveis séricos de vitamina B12 com glicemia basal (P = 0,002) e HOMA-IR (P = 0,040) foi mostrada. Conclusões: Foi observada uma relação inversa significativa entre os níveis de vitamina B12 e glicemia basal e HOMA-IR. Esses achados destacam a deficiência de vitamina B12 em mulheres na pós-menopausa e sugerem suplementação nutricional (AU).
Subject(s)
Humans , Female , Middle Aged , Aged , Vitamin B Complex , Insulin Resistance , Cardiovascular Diseases/epidemiology , Postmenopause , Colombia , Caribbean RegionABSTRACT
To explore the relationship between the early or delayed age at natural menopause and metabolic syndrome (MS) in women. A total of 4 734 natural menopausal women who completed the baseline survey from November 2017 to January 2020 in the Guangzhou Middle-aged and Elderly Chronic Disease Prospective Cohort Study were selected in this cross-sectional study. Data on general demographic characteristics, disease history and female physiological health indicators were collected. Logistic regression model and restricted cubic spline curve were used to analyze the relationship between the age at natural menopause and MS. The results showed that the mean age of the subjects was (60±6) years old. The median (Q1,Q3) age at natural menopause was 50 (49, 52) years old, and the prevalence of MS was 14.8%(699/4 734). After adjusting for confounders, the age at natural menopause was closely related to MS in an approximate"U"shape. Compared with the group of normal age at natural menopause, the early age at menopause (OR=1.52, 95%CI: 1.12-2.06) and delayed age at menopause (OR=1.77, 95%CI: 1.36-2.30) had a higher risk of MS. In the group with time since menopause ≤6 years and 7-9 years, the risk of MS in the group with delayed age at menopause was 2.40 times (95%CI: 1.54-3.75) and 2.19 times (95%CI: 1.11-4.31) higher than that in the group with normal menopausal age, respectively. In conclusion, the early and delayed age at natural menopause increased the risk of MS. The increased risk of MS in delayed age at natural menopause mainly occurred within 10 years since menopause.
Subject(s)
Middle Aged , Aged , Female , Humans , Child , Postmenopause , Metabolic Syndrome/epidemiology , Prospective Studies , Cross-Sectional Studies , Menopause/physiology , Risk FactorsABSTRACT
Postmenopausal osteoporosis is a kind of degenerative disease, also described as "invisible killer." Estrogen is generally considered as the key hormone for women to maintain bone mineral content during their lives. Iron accumulation refers to a state of human serum ferritin that is higher than the normal value but less than 1000 μg/L. It has been found that iron accumulation and osteoporosis could occur simultaneously with the decrease in estrogen level after menopause. In recent years, many studies indicated that iron accumulation plays a vital role in postmenopausal osteoporosis, and a significant correlation has been found between iron accumulation and fragility fractures. In this review, we summarize and analyze the relevant literature including randomized controlled trials, systematic reviews, and meta-analyses between January 1996 and July 2022. We investigate the mechanism of the effect of iron accumulation on bone metabolism and discuss the relationship of iron accumulation, osteoporosis, and postmenopausal fragility fractures, as well as the main clinical treatment strategies. We conclude that it is necessary to pay attention to the phenomenon of iron accumulation in postmenopausal women with osteoporosis and explore the in-depth mechanism of abnormal bone metabolism caused by iron accumulation, in order to facilitate the discovery of effective therapeutic targets for postmenopausal osteoporosis.
Subject(s)
Humans , Female , Osteoporotic Fractures , Osteoporosis, Postmenopausal/drug therapy , Postmenopause , Osteoporosis , Bone Density , Estrogens , Iron/therapeutic useABSTRACT
OBJECTIVE@#To evaluate the effect of denosumab on bone mineral density around proximal femoral prosthesis after total hip arthroplasty(THA) in the postmenopausal osteoporotic patients.@*METHODS@#Fifty-four consecutive patients underwent unilateral primary THA were included in this retrospective study. Twenty-five patients received denosumab for osteoporosis as the treatment group, and the twenty-nine without denosumab were the control group. At 1 week, 3month, 6 months, and 12 months after THA, bone turnover markers and proximal femoral periprosthetic bone mineral density (BMD) were measured.@*RESULTS@#At 3, 6 and 12 months after operation, the level of TRACP-5b in the control group was significantly higher than that in the treatment group (P<0.05);the level of bone-specific alkaline phosphatase (BALP) between two groups showed significant difference in 12 months after operation (control group was higher than treatment group, P<0.05). The BMD of Gruen 1 and Gruen 7 decreased at 3, 6 and 12 months after operation compared with 1 week after operation. Comparing the treatment group and the control group, the differences of the the decrease of BMD in Gruen 1 and Gruen 7 were no significant at 3 months after surgery. In Gruen 1, Gruen 7 at 6 months after operation and Gruen 1, Gruen 7 at 12 months after operation, the decrease of BMD in the control group was significantly higher than that in the treatment group(P<0.05). It is suggested that desudumab could inhibit the loss of BMD after 6 months, and continuously show a protective effect on bone mass at 12 months after operation.@*CONCLUSION@#After THA in postmenopausal patients with osteoporotic femoral neck fracture, Desuzumab can reduce the loss of BMD around the proximal femoral prosthesis and effectively inhibit bone resorption.
Subject(s)
Humans , Arthroplasty, Replacement, Hip , Bone Density , Denosumab/therapeutic use , Retrospective Studies , Postmenopause , Absorptiometry, Photon , Bone Remodeling , Follow-Up Studies , Hip ProsthesisABSTRACT
Introduction: Some studies have described impairment in quality of life of vitamin-deficient subjects. However, little is known about this association in primary care. This study aimed to evaluate the association between vitamin D deficiency and quality of life in postmenopausal women attending primary care in the municipality of Santa Maria Brazil. Methods: A cross-sectional study was carried out with postmenopausal women over 55 years of age, accompanied in primary care, from March to August 2014. These women were randomly selected among the participants of a cohort study in the municipality of Santa Maria Brazil. Data were collected through a standardized questionnaire, quality of life was assessed using the Short Form-36 Health Survey (SF-36), and 25-hydroxyvitamin D were measured using the ALPCO® ELISA method. Results: Of the total of 78 studied women, 11.54% had vitamin D deficiency. Women with vitamin D deficiency had a poorer quality of life assessed by SF-36. In the regression analysis, both vitamin D deficiency and falls were independently associated with a lower physical component of the SF-36. Conclusion: Vitamin D deficiency is associated with poorer quality of life in the studied postmenopausal women.
Subject(s)
Humans , Female , Middle Aged , Aged , Aged, 80 and over , Quality of Life , Vitamin D , Vitamin D Deficiency , Postmenopause , Primary Health Care , Surveys and QuestionnairesABSTRACT
Introdução: Muitas mulheres sofrem com sintomas associados à menopausa, que podem apresentar diferentes graus de intensidade e afetar sua qualidade de vida. Objetivo: Identificar a prevalência e severidade dos principais sintomas nas diferentes fases do climatério. Métodos: Foram selecionadas mulheres com idades entre 40 e 65 anos, que responderam a um questionário on-line com dados sociodemográficos, de saúde, alimentação e características menstruais e de menopausa. Para avaliar os sintomas da menopausa e sua intensidade, foi aplicado o questionário internacional validado Menopause Rating Scale (MRS). Resultados: Foram incluídas 283 mulheres (36,8% na pré-menopausa, 24% na perimenopausa e 39,2% na pós-menopausa). Excesso de peso foi mais prevalente na perimenopausa do que na pré-menopausa (P=0,012). Sintomas como diminuição da libido, secura vaginal, incontinência urinária, dores musculares e articulares, alterações lipídicas e ondas de calor, calorões, foram mais prevalentes em valores absolutos nas mulheres pós-menopausa. As mulheres no período de perimenopausa apresentaram maior prevalência, em valores absolutos, de estresse, irritabilidade, dor de cabeça, problemas na pele, falta de concentração/memória, distúrbios do sono e fadiga. De acordo com o MRS, não houve diferença no domínio psicossocial (P=0,265) e os sintomas somato-vegetativos e urogenitais são mais intensos nas mulheres na perimenopausa e pós-menopausa, quando comparadas com as mulheres na pré-menopausa (P<0,001). O escore global do questionário também demonstra essa intensidade menor no grupo pré-menopausa (P=0,001). Conclusões: Este estudo demonstrou uma prevalência e severidade maior de sintomas em mulheres na perimenopausa e pós-menopausa, o que pode prejudicar a qualidade de vida dessas mulheres nessa fase da vida
Introduction: Many women experience symptoms associated with menopause that present with different degrees of intensity and affect their quality of life. Objective: To identify the prevalence and severity of the main symptoms during different climacteric phases. Methods: Women aged 4065 years answered an online questionnaire on sociodemographic data, health, diet, menstrual, and menopausal characteristics. The internationally validated Menopause Rating Scale (MRS) questionnaire was used to assess menopausal symptoms and their intensities. Results: 283 women were included (36.8% pre-menopausal, 24% peri-menopausal, and 39.2% post-menopausal). Excess weight was more prevalent in the peri-menopausal group than in the pre-menopausal group (P=0.012). Symptoms such as decreased libido, vaginal dryness, urinary incontinence, muscle and joint pain, lipid alterations, and hot flashes were more prevalent in the absolute values of post-menopausal women. Women in the peri-menopausal period had a higher prevalence, in absolute values, of stress, irritability, headache, skin problems, lack of concentration/memory, sleep disorders, and fatigue. According to the MRS, there was no difference in the psychosocial domain (P=0.265) but somato-vegetative and urogenital symptoms are more intense in peri-menopausal and post-menopausal women when compared to pre-menopausal women (P<0.001). The global score on the questionnaire also demonstrated a lower intensity in the pre-menopausal group's symptoms (P=0.001). Conclusions: This study demonstrated a higher prevalence and severity of symptoms in peri-menopausal and post-menopausal women, which may impair the quality of life of these women at this stage of life.
Subject(s)
Humans , Female , Quality of Life , Climacteric , Menopause , Prevalence , Cross-Sectional Studies , Women's Health , Premenopause , Postmenopause , Perimenopause , DietABSTRACT
Objective: To compare the affective response of postmenopausal women who undergo 6 weeks of resistance training on stable and unstable surfaces. Methods: This randomized counterbalanced cross-over study carried included 14 postmenopausal women (55 [SD, 3] years; height 1.55 [SD, 0.03] m; body mass 78.70 [SD, 12.00] kg; and body mass index 32.80 [SD, 4.90] kg/m²), who underwent 6 weeks of resistance training on stable and unstable surfaces. The participants were initially allocated to 1 experimental condition (stable or unstable) in a randomized counterbalanced manner. The intervention consisted of 8 exercises in 3 series of 8-10 repetitions, with intervals of 60-90 seconds, for 3 weeks. After the first 3-week protocol, they were switched to the other experimental condition for another 3 weeks. To evaluate affective response, the Hardy and Rejeski Sensation Scale was applied weekly at the end of each exercise and again at the end of the 6 weeks. Results: Affective response was similar to the general affect observed at the end of the sessions (stable surface: 5.00 [3.00]; unstable surface: 5.00 [1.00]; p = 0.114), except for the bridge exercise (stable surface: 3.00 [2.00]; unstable surface: 4.00 [2.00]; p = 0.048]). Conclusions: The affective response of these women was not affected by training on unstable surfaces, except for the bridge exercise, in which the unstable surface increased affective response
Objetivo: Comparar as respostas afetivas de mulheres pós-menopausadas submetidas a seis semanas de treinamento com pesos realizado em superfície estável e instável. Metodologia: Trata-se de um estudo cross-over, randomizado e contrabalanceado realizado com 14 mulheres pós-menopausadas (55 ± 3 anos; estatura de 1,55 ± 0,03 m; massa corporal 78,70 ± 12,00 kg; e índice de massa corporal de 32,80 ± 4,90 kg/m²) submetidas a seis semanas de treinamento com pesos em superfície estável e instável. As participantes foram alocadas, inicialmente, numa das condições experimentais de forma randomizada e contrabalanceada. A intervenção foi composta por oito exercícios em três séries de oito a dez repetições, com intervalos entre 60 e 90 segundos, durante três semanas. Para avaliação das respostas afetivas, foi aplicada a Escala de Sensação de Hardy e Rejeski ao fim da última série de cada exercício e ao final das sessões, durante as seis semanas. Resultados: As respostas afetivas foram similares para o afeto geral observado ao final das sessões [Superfície estável: 5,00 (3,00); Superfície instável: 5,00 (1,00); p = 0,114], mas não para o exercício de ponte [Superfície estável: 3,00 (2,00); Superfície instável: 4,00 (2,00); p = 0,048)]. Conclusões: Conclui-se que as respostas afetivas de mulheres pós-menopausadas, observadas ao final da sessão, não foram afetas pela instabilidade. Contudo, as sensações de prazer, no exercício de ponte, foram maiores com a inserção da instabilidade
Subject(s)
Humans , Female , Middle Aged , Postmenopause/physiology , Postmenopause/psychology , Affective Symptoms/psychology , Exercise Therapy/methods , Cross-Over StudiesABSTRACT
Abstract Objective To evaluate the efficacy of the hormonal and nonhormonal approaches to symptoms of sexual dysfunction and vaginal atrophy in postmenopausal women. Data Sources We conducted a search on the PubMed, Embase, Scopus, Web of Science, SciELO, the Cochrane Central Register of Controlled Trials (CENTRAL), and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases, as well as on clinical trial databases. We analyzed studies published between 1996 and May 30, 2020. No language restrictions were applied. Selection of Studies We selected randomized clinical trials that evaluated the treatment of sexual dysfunction in postmenopausal women. Data Collection Three authors (ACAS, APFC, and JL) reviewed each article based on its title and abstract. Relevant data were subsequently taken from the full-text article. Any discrepancies during the review were resolved by consensus between all the listed authors. Data Synthesis A total of 55 studies were included in the systematic review. The approaches tested to treat sexual dysfunction were as follows: lubricants and moisturizers (18 studies); phytoestrogens (14 studies); dehydroepiandrosterone (DHEA; 8 studies); ospemifene (5 studies); vaginal testosterone (4 studies); pelvic floor muscle exercises (2 studies); oxytocin (2 studies); vaginal CO2 laser (2 studies); lidocaine (1 study); and vitamin E vaginal suppository (1 study). Conclusion We identified literature that lacks coherence in terms of the proposed treatments and selected outcome measures. Despite the great diversity in treatment modalities and outcome measures, the present systematic review can shed light on potential targets for the treatment, which is deemed necessary for sexual dysfunction, assuming that most randomized trials were evaluated with a low risk of bias according to the Cochrane Collaboration risk of bias tool. The present review is registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42018100488).
Resumo Objetivo Avaliar a eficácia das abordagens hormonais e não hormonais para os sintomas de disfunção sexual e atrofia vaginal em mulheres na pós-menopausa. Fontes de Dados Pesquisamos as bases de dados PubMed, Embase, Scopus, Web of Science, SciELO, Cochrane Central Register of Controlled Trials (CENTRAL), e Cumulative Index to Nursing and Allied Health Literature (CINAHL), assim como bancos de dados de ensaios clínicos. Foram analisados estudos publicados entre 1996 e 30 de maio de 2020. Nenhuma restrição de idioma foi aplicada. Seleção dos Estudos Foram selecionados ensaios clínicos randomizados que avaliavam o tratamento das disfunções sexuais em mulheres na pós-menopausa. Coleta de Dados Três autores (ACAS, APFC e JL), revisaram cada artigo com base em seu título e resumo. Os dados relevantes foram posteriormente retirados do texto completo do artigo. Quaisquer discrepâncias durante a revisão foram resolvidas por consenso entre todos os autores listados. Síntese dos Dados Ao todo, 55 estudos foram incluídos na revisão sistemática. As abordagens testadas para tratar a disfunção sexual foram: lubrificantes e hidratantes (18 estudos); fitoestrogênios (14 estudos); deidroepiandrosterona (DHEA; 8 estudos); ospemifeno (5 estudos); testosterona vaginal (4 estudos); exercícios para os músculos do assoalho pélvico (2 estudos); oxitocina (2 estudos);laser de CO2 vaginal (2 estudos); lidocaína (1 estudo), e vitamina E vaginal (1 estudo). Conclusão Identificou-se falta de coerência na literatura quanto aos tratamentos propostos e medidas de resultados selecionadas. Apesar da grande diversidade de modalidades de tratamento e medidas de resultados, esta revisão sistemática pode lançar luz sobre alvos potenciais para o tratamento, que é considerado necessário para a disfunção sexual, assumindo que a maioria dos estudos randomizados foi avaliada com baixo risco de viés de acordo com a ferramenta de avaliação de risco de viés de Cochrane Collaboration. Esta revisão tem cadastro no International Prospective Register of Systematic Reviews (PROSPERO; CRD42018100488).
Subject(s)
Humans , Female , Orgasm , Sexual Dysfunction, Physiological , Postmenopause , Dyspareunia , Estrogens/therapeutic useABSTRACT
BACKGROUND: A secondary cause can be found in up to one third of women with osteoporosis, potentially modifying their therapeutic approach. AIM: To determine the prevalence of secondary causes and risk factors for decreased bone mineral density (BMD) and osteoporosis. Material and Methods: We included postmenopausal women with a diagnosis of osteoporosis or low BMD who consulted for the first time in an endocrinology clinic between October 2018 and March 2020. A complete medical history, physical examination and a standardized laboratory assessment to identify secondary causes were performed. RESULTS: During the study period, 114 women were evaluated, 30 of them with low BMD and 84 with osteoporosis. After obtaining a medical history and a structured laboratory screening, at least one secondary cause was found in 50% of patients with osteoporosis and in 67% of those with low BMD. Most patients with no identified secondary cause had at least one risk factor for fragility fractures. Conclusions: A structured evaluation that includes medical history and standardized laboratory study in postmenopausal women with osteoporosis or low BMD, is a valuable tool to identify secondary causes of osteoporosis.
Subject(s)
Humans , Male , Osteoporosis/etiology , Osteoporosis/epidemiology , Fractures, Bone/complications , Fractures, Bone/epidemiology , Bone Density , Postmenopause , MineralsABSTRACT
Objective: To understand the prevalence of osteoporosis and related factors in postmenopausal women aged ≥40 years in China and provide scientific evidence for osteoporosis prevention and control. Methods: Data of this study were from the 2018 China Osteoporosis Epidemiological Survey, covering 44 counties (districts) in 11 provinces in China. Related variables were collected by questionnaire survey and physical measurement, and the BMD of lumbar spine and proximal femur was measured by dual-energy X-ray absorption method. The prevalence of osteoporosis and its 95%CI in postmenopausal women aged ≥40 years were estimated with complex sampling weights. Results: A total of 5 728 postmenopausal women aged ≥40 years were included in the analysis and the prevalence of osteoporosis was 32.5% (95%CI: 30.3%-34.7%). The prevalence of osteoporosis in postmenopausal women aged 40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years were 16.0% (95%CI:4.5%-27.5%), 18.4% (95%CI:15.9%-20.8%), 37.5% (95%CI:34.5%-40.4%), 52.9% (95%CI: 47.5%-58.3%), and 68.0% (95%CI:55.9%-80.1%) respectively. The prevalence of osteoporosis was higher (P<0.001) in those with education level of primary school or below (47.2%, 95%CI: 43.0%-51.3%) and in those with individual annual income less than 10 000 Yuan, (40.3%, 95%CI: 36.9%-43.7%). The prevalence of osteoporosis was 35.1% in rural areas (95%CI: 32.0%-38.1%), which was higher than that in urban areas (P<0.001). The prevalence of osteoporosis in low weight, normal weight, overweight and obese groups were 69.9% (95%CI: 59.0%-80.8%), 42.2% (95%CI: 38.7%-45.7%), 24.2% (95%CI: 21.3%-27.1%) and 14.6% (95%CI: 11.1%-18.0%), respectively. The prevalence of osteoporosis in those with menstrual maintenance years ≤30 years and in those with menopause years ≥11 years were 46.1% (95%CI:40.8%-51.3%) and 48.2% (95%CI:45.0%-51.3%), respectively. Multivariate logistic analysis showed that age ≥60 years, education level of primary school or below, annual household income per capita less than 10 000 Yuan, low body weight, menstrual maintenance years ≤30 years, menopause years ≥11 years were risk factors of osteoporosis in postmenopausal women in China. Conclusions: The prevalence of osteoporosis was high in postmenopausal women aged ≥40 years in China, and there were differences in osteoporosis prevalence among different socioeconomic groups. Effective interventions should be taken for the prevention and control of osteoporosis in key groups in the future.